Compare Cassava Sciences Inc (FLNA) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Tyson Foods, Inc. — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Tyson Foods, Inc. trades at $53.35 (market cap $18.41B). The key difference: Tyson Foods, Inc. is far larger — about 467.3× Cassava Sciences Inc's market cap, and Tyson Foods, Inc. pays a 3.9% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Tyson Foods, Inc. for 76 Days on average.
| FLNA | TSN | |
|---|---|---|
Market Cap | $39.40M | $18.41B |
Volume | 759,018 | 3,757,599 |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $68.75 |
52-Week Low | $0.68 | $50.47 |
Typical Hold Time | 37 Days | 76 Days |
Enterprise Value | -$43.28M | $25.68B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Tyson Foods (TSN) trades at $52.70, up 1.93% with mixed technical signals showing bullish overall but bearish moving averages. The company reported Q2 2026 EPS of $0.99 beating expectations, though revenue growth remains modest at 1.5%-2.0% for 2026. Analysts maintain a Buy consensus with $65.40 target, but recent news highlights investigations into guidance revisions and beef segment challenges.
Outlook remains cautious with upside potential from execution improvements, but risks include beef segment losses, margin pressure, and ongoing securities investigations. The stock offers value with low P/S of 0.33 and consistent dividends, but requires monitoring of operational turnaround and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
